NEW YORK--(BUSINESS WIRE)--Thorne Research, Inc., announced today that Mitsui, one of Japan’s largest trading companies and part of the Mitsui Group, has made a strategic investment in Thorne, with the purpose of expanding business in the United States and Japan.
After a thorough review of Thorne’s business platform, Mitsui decided to expand its wellness business in Japan, utilizing Thorne’s nutritional supplement products and diagnostic testing platforms. Mitsui plans to launch collaborations with other Japanese companies for wellness product development and distribution, and joins the Helsinn Group as the second international strategic investor in Thorne.
“We are proud to partner with Mitsui because Mitsui is a great cultural fit for us due to their strong appreciation for science and research,” said Paul Jacobson, Thorne’s CEO. “By tapping into Mitsui’s $40 billion annual sales network, we will be able to expand our strategic relationships in ways we could not achieve alone.”
The investment will allow Thorne to dramatically expand its U.S. platform. After years of work and planning, the investment paves the way for Thorne to broaden its reach in personalized health care by expanding into home testing platforms. Utilizing its large health care practitioner network, its research and content collaboration with Mayo Clinic, and its sophisticated analytical software, Thorne’s goal is to become the market leader in bringing prevention and wellness into the homes of consumers in 2018.
“As a result of this investment, we expect to make several big key announcements over the next two months as we present a new platform to the marketplace,” added Jacobson.
“We invested in Thorne’s supplement and testing platform because it meets the high-quality standards we set for ourselves in the heavily regulated Japanese market,” stated Masami Yokoyama, General Manager, NutriScience Division, at Mitsui. “As in other leading nations, the Japanese health care system is searching for ways to keep its population healthy through more natural approaches, so Thorne’s commitment to proving that its products work through testing and research make them the ideal partner for us.”
Thorne is a health and technology company that is disrupting prevention and wellness. By combining dietary and lifestyle recommendations with nutritional supplement intervention, Thorne is at the forefront of personalized health, with a mission to help consumers take control of their own health and live a healthy life. Thorne provides at-home blood biomarker tests to bring the doctor to the consumer’s home. By leveraging its sophisticated analytical software, Thorne helps consumers uncover health insights and confidently take action to optimize healthier outcomes. Based on individual test results, Thorne’s technology and team can deliver a personalized plan on what to eat, how to exercise, and what Thorne supplements to take.
Thorne is the only supplement manufacturer to collaborate with Mayo Clinic on wellness research and content, and is the proud partner of a number of U.S. National Teams, including U.S. Soccer, USA Hockey, USA Triathlon, and USA Rowing. Thorne is one of the fastest growing supplement companies, and is rated the top practitioner-dispensed brand among 30-40 year olds. For more information visit https://www.thorne.com/.
Mitsui & Co., Ltd., is a diversified global trading, investment, and service enterprise, headquartered in Tokyo, Japan. Mitsui & Co. pursues “360° business innovation” that ranges from product sales, worldwide logistics and financing, through to the development of major international infrastructure and other projects. It maintains a global network of 137 offices in 65 countries/regions, and has 462 group companies and associated companies worldwide.
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the lives of patients, guided by core family values of respect, integrity and quality. Helsinn Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements, and has expertise in research, development, manufacturing, and the commercialization of therapeutic and supportive care for cancer, pain, inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early- stage investment opportunities in areas of unmet patient needs. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing, and in 2017, established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the United States, as well as a product presence in 190 countries globally.